EyePoint, Inc.
EYPTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeEyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. With a market capitalization of $1.14B, it sits in small-cap territory. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Market Cap
$1.14B
Beta
1.77
P/E (TTM)
—
P/E (Fwd)
-4.74
EPS (TTM)
$-3.51
EPS (Fwd)
$-2.87
ROE
-102.7%
ROA
-54.1%
Cash
$45.3M
Total Debt
$17.6M
Free CF
-$168.7M
52W Change
83.0%
Annual Financials
Cash vs Debt
With $45.3M in cash and $17.6M in debt, EYPT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$168.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -102.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $41.4M (2022) to $31.4M (2025), a 24% decline worth watching.
With a beta above 1.5, EYPT tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, EYPT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for EyePoint, Inc. and its sector.